Breaking the Batch Paradigm: Continuous Biomanufacturing at Commercial Scale

As biologics portfolios expand and biosimilar competition increases, manufacturers are seeking new approaches to improve productivity, reduce cost of goods, and ensure supply continuity. Continuous biomanufacturing offers an agile alternative to traditional batch processing by enabling higher output, enhanced process consistency, and greater facility utilization within a smaller manufacturing footprint.

This presentation will explore how continuous biomanufacturing can be applied at commercial scale to support late-phase candidates, commercial biologics, and biosimilars. Integrated continuous processes can accelerate tech transfer, improve operational flexibility, and enable rapid capacity deployment while reducing capital investment requirements.They support scalable, resilient, and cost-effective commercial supply strategies.

The session will provide insights for biopharma leaders evaluating next-generation manufacturing models to meet growing market demand while enhancing competitiveness and long-term supply security.